2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 401

Racial and Ethnic Disparities in Depression Diagnosis and Treatment for Adolescents with SLE: Analysis of a National Medicaid Sample
Abstract Number: 1459

Racial Comparisons of Children with Idiopathic Uveitis: Results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Abstract Number: 2124

Racial Disparities in Lupus Pregnancy
Abstract Number: 1423

Racial Disparities in Pain and Function after Total Knee Arthroplasty in the United States: A Systematic Literature Review
Abstract Number: 2109

Racial Disparities in the Risk of Hospitalized Severe Allopurinol Hypersensitivity Syndrome – a US Nationwide Study (2009-2011)
Abstract Number: 2253

Racial Disparities in Total Shoulder Arthroplasty Utilization and Outcomes Are Persisting
Abstract Number: 1279

Racial Variation in Total Knee Replacement in a Diverse Community-Based Clinical Trial
Abstract Number: 1312

Radiocarpal Cartilage Matrix Changes 3-Months after Anti-TNF Treatment for Rheumatoid Arthritis – Feasibility Study Using MR T1ρ� Imaging
Abstract Number: 340

Radiographic Assessment of Hand Osteoarthritis – the Role of Oblique View Images
Abstract Number: 1731

Radiographic Damage of Facet Joints and Vertebral Bodies in the Cervical Spine in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors
Abstract Number: 462

Radiographic Progression in Patients with Early Rheumatoid Arthritis Has Not Become Milder over the Past Decades
Abstract Number: 2054

Randomized, Double-Blind, Phase 3 Study of Efficacy and Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 16

Rantes/CCL5 Selectively Induces MMP-1 and MMP-13 Production in Rheumatoid Arthritis Synovial Fibroblasts Via PKC-Î´ and JNK Pathways
Abstract Number: 1670

Rapidity of Therapeutic Response of Biologics Compared to Methotrexate Monotherapy in Early RA: A Network Meta-Analysis
Abstract Number: 655

Rasch Analysis of the Hospital Anxiety and Depression Scale in Psoriatic Arthritis: Results from the Presta Study.

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].